Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GBI Research Report Guidance
2.2 Disease Introduction
2.3 Epidemiology
2.4 Etiology and Pathophysiology
2.4.1 Adenocarcinoma
2.4.2 Squamous Cell Carcinoma
2.4.3 Large Cell Carcinoma
2.4.4 Immunotherapy
2.5 Symptoms
2.6 Diagnosis
2.7 Prognosis
2.8 Treatment
2.8.1 Treatment Algorithm
2.8.2 First-Line Treatment
2.8.3 Maintenance Therapy
2.8.4 Second-Line Therapy
2.8.5 Third-Line Therapy
2.8.6 Adjuvant Therapy
3 Marketed Products
3.1 Overview
3.2 Chemotherapies – Various
3.2.1 Cisplatin
3.2.2 Carboplatin
3.2.3 Vinorelbine
3.2.4 Paclitaxel
3.2.5 Docetaxel
3.2.6 Gemcitabine
3.3 Alimta – Eli Lilly
3.4 Abraxane – Celgene Corporation
3.5 Tarceva – Roche
3.6 Iressa – AstraZeneca
3.7 Gilotrif – Boehringer Ingelheim
3.8 Xalkori – Pfizer
3.9 Avastin (bevacizumab) – Roche
3.10 Marketed Products Heatmap
3.11 Conclusion
4 NSCLC Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Clinical Trial Primary Endpoints
4.4 Late-Stage Pipeline Product Profiles
4.4.1 Custirsen – Teva Pharmaceutical Industries
4.4.2 Halaven – Eisai
4.4.3 Dacomitinib – Pfizer
4.4.4 Vargatef – Boehringer Ingelheim
4.4.5 Necitumumab – Eli Lilly
4.4.6 Ganetespib – Synta Pharmaceuticals
4.4.7 Zykadia– Novartis
4.4.8 Yervoy – Bristol Myers Squibb
4.4.9 Nivolumab – Ono Pharmaceuticals/Bristol-Myers Squibb
4.4.10 MK-3475 – Merck
4.4.11 RG7446 – Roche
4.4.12 Cyramza– Eli Lilly
4.4.13 Tavocept – BioNumerik Pharmaceuticals
4.4.14 Tecemotide – Merck Serono
4.4.15 Tertomotide – KAEL-GemVax
4.4.16 Lucanix – NovaRx Corporation
4.4.17 Bevacizumab Biosimilar – Various
4.5 Safety and Efficacy Heatmap
4.6 Conclusion
4.6.1 Product Competitiveness Framework
4.6.2 Future Treatment Algorithm
5 Market Forecast
5.1 Geographical Markets
5.1.1 Global Markets
5.1.2 North America
5.1.3 Top Five EU Countries
5.1.4 Japan
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers
6 Strategic Consolidations
6.1 Major Co-Development deals
6.1.1 Merck Enters into Co-Development Agreement with Endocyte
6.1.2 Exelixis Enters into a Co-Development Agreement with Genentech
6.1.3 CancerVax Enters into an Agreement with CIMAB and YM Biosciences
6.1.4 SFJ Pharma Enters into Co-Development Agreement with Pfizer for Dacomitinib
6.1.5 OxOnc Development Enters into Co-Development Agreement with Pfizer for Crizotinib
6.2 Major Licensing Deals
6.2.1 Merck Serono Enters into Licensing Agreement with Ono Pharma
6.2.2 Astellas Pharma Enters into Licensing Agreement with Aveo Pharma
6.2.3 Clovis Oncology Enters into a Licensing Agreement with Avila Therapeutics
6.2.4 Novartis Enters into Licensing Agreement with Antisoma
6.2.5 Cell Therapeutics Enters into Licensing Agreement with Novartis
7 Appendix
7.1 References
7.2 Market Definition
7.3 Abbreviations
7.3.1 Research Methodology
7.3.2 Secondary Research
7.3.3 Marketed Product Profiles
7.3.4 Late-Stage Pipeline Candidates
7.3.5 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
7.3.6 Product Competitiveness Framework
7.3.7 Pipeline Analysis
7.3.8 Forecasting Model
7.3.9 Deals Data Analysis
7.4 Contact Us
7.5 Disclaimer